Vaxart (NASDAQ:VXRT) Price Target Lowered to $2.00 at B. Riley

Vaxart (NASDAQ:VXRT - Get Free Report) had its price objective lowered by research analysts at B. Riley from $2.50 to $2.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the biotechnology company's stock. B. Riley's price objective would suggest a potential upside of 391.40% from the stock's current price.

Vaxart Stock Down 3.4 %

Shares of VXRT stock traded down $0.01 during mid-day trading on Thursday, hitting $0.41. 2,327,707 shares of the stock were exchanged, compared to its average volume of 2,374,588. Vaxart has a 52-week low of $0.39 and a 52-week high of $1.34. The company has a market cap of $92.78 million, a PE ratio of -0.99 and a beta of 1.69. The firm has a fifty day moving average of $0.62 and a 200 day moving average of $0.69.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.05. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. The business had revenue of $15.19 million during the quarter, compared to analysts' expectations of $15.68 million. Equities analysts predict that Vaxart will post -0.39 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Graham Capital Management L.P. grew its stake in Vaxart by 155.8% during the 4th quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 32,482 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in shares of Vaxart by 140.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 35,213 shares during the period. Invesco Ltd. increased its holdings in Vaxart by 48.6% in the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 24,803 shares during the last quarter. XTX Topco Ltd raised its position in Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock valued at $116,000 after purchasing an additional 122,387 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Vaxart by 10.8% in the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock valued at $122,000 after buying an additional 17,942 shares in the last quarter. 18.05% of the stock is owned by hedge funds and other institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.